{"id":10396,"date":"2025-06-29T03:43:09","date_gmt":"2025-06-29T01:43:09","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=10396"},"modified":"2025-06-29T03:43:18","modified_gmt":"2025-06-29T01:43:18","slug":"autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/","title":{"rendered":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset"},"content":{"rendered":"<p><img data-recalc-dims=\"1\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/dealbreaker.com\/.image\/c_fit%2Ch_800%2Cw_1200\/MjE1OTE5NjM3MDA5ODAyNjA3\/test-tubes.jpg?w=1140&#038;ssl=1\" \/><\/p>\n<p><b>Vor Biopharma<\/b>, a pioneer in <b>cancer cell therapy<\/b>, has recently made headlines as it reestablishes itself after laying off nearly its entire workforce during an operational wind-down last month. The company has emerged under new leadership, with a strategic focus on <b>autoimmune diseases<\/b>, supported by an impressive $175 million financing package. This renewed direction indicates a significant pivot from its previous endeavors.<\/p>\n<p>The <b>Cambridge, Massachusetts<\/b>-based Vor Biopharma announced on Wednesday that it has secured exclusive rights to <b>telitacicept<\/b>, a promising drug candidate that <b>RemeGen<\/b> has successfully guided through regulatory approvals in <b>China<\/b> for conditions such as <b>generalized myasthenia gravis<\/b> (gMG), <b>systemic lupus erythematosus<\/b>, and <b>rheumatoid arthritis<\/b>. While RemeGen retains the rights to the drug within China, Vor holds the exclusive rights necessary to develop and commercialize the drug in other territories, which is currently undergoing a global Phase 3 study for gMG that could support an FDA submission.<\/p>\n<p>In cases of gMG, autoantibodies attack critical proteins essential for effective communication between nerves and muscles. This rare disorder manifests as symptoms such as difficulty swallowing and pronounced muscle weakness. The progression of gMG is primarily driven by a type of immune cell known as a <b>B cell<\/b>. Vor\u2019s innovative drug functions as a fusion protein specifically engineered to selectively inhibit <b>B cell activating factor<\/b> (BAFF), also referred to as <b>BlyS<\/b>, and <b>APRIL<\/b>, both of which are integral to maintaining B cell survival.<\/p>\n<p>While Vor Biopharma is not alone in targeting these pivotal mechanisms, its concentrated approach to gMG could set it apart from competitors in the field. For instance, <b>Novartis<\/b> has developed <b>zigakibart<\/b>, a monoclonal antibody that blocks APRIL and is currently in Phase 3 testing for <b>immunoglobulin A nephropathy<\/b> (IgAN). Similarly, <b>Vera Therapeutics<\/b> is pursuing BAFF and APRIL inhibition with its fusion protein, <b>atacicept<\/b>, which recently met its Phase 3 goals in IgAN, with an FDA submission anticipated in the fourth quarter of this year. Additionally, <b>Vertex Pharmaceuticals<\/b> is advancing its fusion protein, <b>povetacicept<\/b>, targeting BAFF and APRIL, which was a focal point in its substantial $4.9 billion acquisition of <b>Alpine Immune Sciences<\/b>.<\/p>\n<p>Recent years have seen the introduction of new therapies for treating gMG, yet none have successfully targeted BAFF and APRIL directly. Available treatments include drugs that inhibit complement proteins associated with gMG, such as <b>AstraZeneca\u2019s Ultomiris<\/b> and <b>UCB\u2019s Zilbrysq<\/b>, as well as <b>FcRn inhibitors<\/b> like <b>Argenx\u2019s Vyvgart<\/b> and <b>Vyvgart Hytrulo<\/b>. The latest FcRn inhibitor for gMG, <b>Johnson &amp; Johnson\u2019s Imaavy<\/b>, received FDA approval in May. Vor has announced that the Phase 3 study for telitacicept is actively enrolling patients across the <b>U.S.<\/b>, <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/europe-wrangles-with-biofuel-oversupply-problems-and-possible-fraud\/\">Europe<\/a><\/b>, and <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/emotionally-unprepared-americans-face-retirement-challenges\/\">South America<\/a><\/b>, with preliminary results expected in the first half of 2027.<\/p>\n<p><b>Vor Biopharma<\/b>, co-founded by acclaimed oncologist <b>Siddhartha Mukherjee<\/b> alongside startup incubator <b>PureTech Health<\/b>, initially focused on developing stem cell-derived therapies for blood cancers, offering alternatives to traditional <b>CART therapies<\/b> that rely on harvesting and engineering a patient\u2019s own T cells. The company went public in 2021, raising nearly $177 million. However, despite progress in clinical-stage programs, Vor faced financial constraints. In May, the company halted its clinical and manufacturing operations, resulting in the layoff of approximately 95% of its workforce while exploring strategic alternatives for its business model.<\/p>\n<p>Following the recent changes, Vor&#8217;s CEO, <b>Robert Ang<\/b>, resigned on Thursday. The company\u2019s board has appointed <b>Jean-Paul Kress<\/b>, the former CEO of <b>MorphoSys<\/b>\u2014which was acquired by Novartis last year\u2014as the new chief executive. Kress also previously led <b>Syntimmune<\/b>, which was acquired by <b>Alexion Pharmaceuticals<\/b>, now part of <b>AstraZeneca\u2019s<\/b> rare diseases subsidiary.<\/p>\n<p>\u201cBy targeting BAFF\/APRIL signaling with telitacicept, we are making a substantial advancement in treating diseases driven by autoantibodies, distinguishing our therapeutics from other modalities in the market,\u201d Kress stated in a prepared statement. \u201cWith this clinically advanced asset, we are uniquely positioned to develop this innovative therapy, with the ambition of making a significant impact for patients battling autoimmune diseases globally.\u201d<\/p>\n<p>In its financial report for the first quarter of 2025, Vor disclosed a cash position of approximately $60 million. Following the telitacicept licensing agreement, the company has bolstered its finances through a $175 million private placement. This financing round includes participation from <b>RA Capital Management<\/b>, an existing shareholder of Vor, alongside other disclosed investors such as <b>Mingxin Capital<\/b>, <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/investor-caution-causes-dip-in-biotech-financing-report-finds\/\">Forbion<\/a><\/b>, <b>Venrock Healthcare Capital Partners<\/b>, <b>Caligan Partners<\/b>, and <b>NEXTBio<\/b>. Vor intends to allocate the proceeds to advance its therapeutic pipeline and for various corporate purposes.<\/p>\n<p>As per Vor\u2019s agreement with RemeGen, Vor is obligated to pay the biotech a total of $125 million, which includes an upfront payment of $45 million along with warrants allowing the purchase of approximately $80 million worth of Vor stock. According to a regulatory filing, RemeGen could earn up to $330 million in regulatory milestone payments and an additional $3.7 billion tied to sales milestones. Moreover, RemeGen will benefit from royalties on sales if the drug successfully reaches the market.<\/p>\n<p> <em>For more insights on the latest trends in litigation, regulation, partnerships, and financial services, consider subscribing to Finance Docket, a collaboration between Breaking Media publications Above the Law and Dealbreaker.<\/em><\/p>\n<p><a href=\"https:\/\/dealbreaker.com\/2025\/06\/vor-bio-reinvents-itself-as-an-autoimmune-biotech-with-in-licensed-phase-3-asset-and-175m-in-funding\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vor Biopharma, a pioneer in cancer cell therapy, has recently made headlines [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10397,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":2,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[887,142],"tags":[],"class_list":["post-10396","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotech-funding","category-finance-business","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"Vor Biopharma, a pioneer in cancer cell therapy, has recently made headlines [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-29T01:43:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-29T01:43:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1067\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset\",\"datePublished\":\"2025-06-29T01:43:09+00:00\",\"dateModified\":\"2025-06-29T01:43:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/\"},\"wordCount\":839,\"commentCount\":1,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1\",\"articleSection\":[\"Biotech Funding\",\"Finance &amp; Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/\",\"name\":\"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1\",\"datePublished\":\"2025-06-29T01:43:09+00:00\",\"dateModified\":\"2025-06-29T01:43:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1\",\"width\":1067,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/","og_locale":"en_US","og_type":"article","og_title":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance","og_description":"Vor Biopharma, a pioneer in cancer cell therapy, has recently made headlines [&hellip;]","og_url":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-06-29T01:43:09+00:00","article_modified_time":"2025-06-29T01:43:18+00:00","og_image":[{"width":1067,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset","datePublished":"2025-06-29T01:43:09+00:00","dateModified":"2025-06-29T01:43:18+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/"},"wordCount":839,"commentCount":1,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","articleSection":["Biotech Funding","Finance &amp; Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/","url":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/","name":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","datePublished":"2025-06-29T01:43:09+00:00","dateModified":"2025-06-29T01:43:18+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","width":1067,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/autoimmune-biotech-vor-bio-secures-175m-for-phase-3-asset\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Autoimmune Biotech Vor Bio Secures $175M for Phase 3 Asset"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/06\/Vor-Bio-Reinvents-Itself-as-an-Autoimmune-Biotech-With-In-Licensed.jpg?fit=1067%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=10396"}],"version-history":[{"count":2,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10396\/revisions"}],"predecessor-version":[{"id":10399,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/10396\/revisions\/10399"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/10397"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=10396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=10396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=10396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}